These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 27576076

  • 1. Optimizing seroprotection against pneumococcus in children with nephrotic syndrome using the 13-valent pneumococcal conjugate vaccine.
    Pittet LF, Posfay-Barbe KM, Chehade H, Rudin C, Wilhelm-Bals A, Rodriguez M, Siegrist CA, Parvex P.
    Vaccine; 2016 Sep 22; 34(41):4948-4954. PubMed ID: 27576076
    [Abstract] [Full Text] [Related]

  • 2. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B, Laudat F, Gurtman A, Patterson S, Sidhu M, Gruber WC, Scott DA.
    Pediatr Infect Dis J; 2014 Oct 22; 33(10):1065-76. PubMed ID: 25093973
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA.
    Vaccine; 2015 Mar 30; 33(14):1719-25. PubMed ID: 25698485
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J, Gurtman A, Bernaola E, Gimenez-Sanchez F, Martinon-Torres F, Pineda-Solas V, Delgado A, Infante-Marquez P, Liang JZ, Giardina PC, Gruber WC, Emini EA, Scott DA.
    Vaccine; 2013 Nov 04; 31(46):5486-94. PubMed ID: 24004465
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3577-84. PubMed ID: 23688526
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3585-93. PubMed ID: 23688527
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.
    Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL, Cole CH, Richmond PC.
    Cancer; 2017 Nov 01; 123(21):4215-4223. PubMed ID: 28696530
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B, B1851020 Study Group.
    Vaccine; 2016 Jun 24; 34(30):3454-62. PubMed ID: 27155493
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
    Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B, 3003 Study Group.
    Clin Infect Dis; 2015 Aug 01; 61(3):313-23. PubMed ID: 25870329
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome.
    Liakou CD, Askiti V, Mitsioni A, Stefanidis CJ, Theodoridou MC, Spoulou VI.
    Vaccine; 2014 Mar 10; 32(12):1394-7. PubMed ID: 24486348
    [Abstract] [Full Text] [Related]

  • 11. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.
    Singleton R, Wenger J, Klejka JA, Bulkow LR, Thompson A, Sarkozy D, Emini EA, Gruber WC, Scott DA.
    Pediatr Infect Dis J; 2013 Mar 10; 32(3):257-63. PubMed ID: 23001026
    [Abstract] [Full Text] [Related]

  • 12. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
    Lee D, Jordan AI, Menges MA, Lazaryan A, Nishihori T, Gaballa SR, Shah BD, Pinilla-Ibarz J, Baluch A, Klinkova OV, Chavez JC, Jain MD, Locke FL.
    Transplant Cell Ther; 2023 Apr 10; 29(4):277.e1-277.e9. PubMed ID: 35970303
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA, Del Nogal B, Fuentes M, Cortez R, Bogaert D, Hermans PW, Waard JH.
    Vaccine; 2014 Jun 30; 32(31):4006-11. PubMed ID: 24837505
    [Abstract] [Full Text] [Related]

  • 14. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
    Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, Patterson S, Gruber WC, Emini EA, Scott DA, 012 Study Group.
    Vaccine; 2012 Dec 14; 30(52):7566-72. PubMed ID: 23099331
    [Abstract] [Full Text] [Related]

  • 15. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
    Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, Hus I, Malm A.
    PLoS One; 2014 Dec 14; 9(12):e114966. PubMed ID: 25506837
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.
    Frenck R, Thompson A, Yeh SH, London A, Sidhu MS, Patterson S, Gruber WC, Emini EA, Scott DA, Gurtman A, 3011 Study Group.
    Pediatr Infect Dis J; 2011 Dec 14; 30(12):1086-91. PubMed ID: 21983216
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    AIDS; 2015 Jul 17; 29(11):1345-54. PubMed ID: 25888646
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.
    Clin Infect Dis; 2013 Oct 17; 57(7):952-62. PubMed ID: 23804191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.